Evidence-based, high-impact
software as medicine.
Click’s platform can target any disease, symptom or side effect with an underlying neurological or behavioral component, including indications in psychiatry, neurology, oncology, immunology, and cardiometabolic diseases.
CT-152
Rejoyn
Indication
Major Depressive Disorder (MDD)
Collaborator
Phase
Launch- AspyreRx
AspyreRx
AspyreRx™
Indication
Type 2 Diabetes
Collaborator
Phase
FDA Cleared - CT-132
CT-132
Indication
Episodic Migraine
Collaborator
Phase
Regulatory Review - CT-155
CT-155
Indication
Schizophrenia
Collaborator
Phase
Phase 3: Pivotal - CT-156
CT-156
Indication
Schizophrenia
Collaborator
Phase
Phase 2: Dev/Pilot - CT-102
CT-102
Indication
Opioid Use Disorder (OUD)
Collaborator
Phase
Phase 2: Dev/Pilot - CT-133
CT-133
Indication
Multiple Sclerosis (MS)
Collaborator
Phase
Phase 1: Discovery - CT-171
CT-171
Indication
Atopic Dermatitis
Collaborator
Phase
Phase 1: Discovery - CT-181
CT-181
Indication
Obesity
Collaborator
Phase
Phase 1: Discovery - CT-191
CT-191
Indication
Oncology
Collaborator
Phase
Phase 1: Discovery - CT-141
CT-141
Clickadian™
Indication
Insomnia
Collaborator
Phase
Phase 1: Discovery - CT-111
CT-111
Clickheart™
Indication
Acute Coronary Syndrome
Collaborator
Phase
Phase 1: Discovery
Product
Indication
Collaborator
Phase
CT-152
Rejoyn
Major Depressive Disorder (MDD)
Launch- AspyreRx
AspyreRx
AspyreRx™
Type 2 DiabetesFDA Cleared - CT-132
CT-132
Episodic MigraineRegulatory Review - CT-155
CT-155
Schizophrenia
Phase 3: Pivotal - CT-156
CT-156
SchizophreniaPhase 2: Dev/Pilot - CT-102
CT-102
Opioid Use Disorder (OUD)Phase 2: Dev/Pilot - CT-133
CT-133
Multiple Sclerosis (MS)Phase 1: Discovery - CT-171
CT-171
Atopic DermatitisPhase 1: Discovery - CT-181
CT-181
ObesityPhase 1: Discovery - CT-191
CT-191
OncologyPhase 1: Discovery - CT-141
CT-141
Clickadian™
InsomniaPhase 1: Discovery - CT-111
CT-111
Clickheart™
Acute Coronary SyndromePhase 1: Discovery
Medicine just got a digital upgrade: Software-Enhanced Drugs™
Click SE™ solutions combine software with pharmacotherapy to create software-enhanced drug™ treatments, to deliver added clinical benefit to patients compared to drug alone.
Contact
Q&A
Stay up to date with news and updates
AspyreRx
AspyreRx™
Indication
Type 2 Diabetes
Phase
FDA ClearedAspyreRx™ is a prescription digital therapeutic intended to provide cognitive behavioral therapy to patients 18 years or older with type 2 diabetes. The device targets adaptive behavior change to aid in the management of type 2 diabetes in patients who are under the care of a healthcare provider. AspyreRx provides cognitive behavioral therapy as a treatment that should be used adjunctively with standard of care.
AspyreRx™ also received FDA Breakthrough Device Designation as a prescription-only digital therapeutic intended to provide cognitive behavioral therapy to patients 18 years or older with a diagnosis of metabolic dysfunction-associated steatohepatitis (MASH). The device targets behavior to aid in the management of MASH in patients who are under the care of a healthcare provider. BT-004 provides cognitive behavioral therapy as a treatment that should be used adjunctively with standard of care.
Click Therapeutics acquired the assets of Better Therapeutics, which includes AspyreRx™, to accelerate its development initiatives in obesity and cardiometabolic disease.
Significant reduction in HbA1c
In a randomized controlled trial in adults with type 2 diabetes and HbA1c of 7 to <11% randomly assigned to AspyreRx app or a control app, both on top of standard of care, patients in the AspyreRx app group had significantly lower HbA1c at 90 days relative the the control arm. A dose response curve was observed based on the number of complete therapy modules. There were no treatment related AEs, discontinuations or deaths due to treatment-emergent AEs.
Publications
Randomized, Controlled Trial of a Digital Behavioral Therapeutic Application to Improve Glycemic Control in Adults With Type 2 Diabetes, Hsia et al.
Read here.
A Novel Prescription Digital Therapeutic Option for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease, Alkhouri et al.
Read here.
AspyreRx
AspyreRx™
Indication
Type 2 Diabetes
Phase
FDA ClearedAspyreRx™ is a prescription digital therapeutic intended to provide cognitive behavioral therapy to patients 18 years or older with type 2 diabetes. The device targets adaptive behavior change to aid in the management of type 2 diabetes in patients who are under the care of a healthcare provider. AspyreRx provides cognitive behavioral therapy as a treatment that should be used adjunctively with standard of care.
AspyreRx™ also received FDA Breakthrough Device Designation as a prescription-only digital therapeutic intended to provide cognitive behavioral therapy to patients 18 years or older with a diagnosis of metabolic dysfunction-associated steatohepatitis (MASH). The device targets behavior to aid in the management of MASH in patients who are under the care of a healthcare provider. BT-004 provides cognitive behavioral therapy as a treatment that should be used adjunctively with standard of care.
Click Therapeutics acquired the assets of Better Therapeutics, which includes AspyreRx™, to accelerate its development initiatives in obesity and cardiometabolic disease.
Significant reduction in HbA1c
In a randomized controlled trial in adults with type 2 diabetes and HbA1c of 7 to <11% randomly assigned to AspyreRx app or a control app, both on top of standard of care, patients in the AspyreRx app group had significantly lower HbA1c at 90 days relative the the control arm. A dose response curve was observed based on the number of complete therapy modules. There were no treatment related AEs, discontinuations or deaths due to treatment-emergent AEs.
Publications
Randomized, Controlled Trial of a Digital Behavioral Therapeutic Application to Improve Glycemic Control in Adults With Type 2 Diabetes, Hsia et al.
Read here.
A Novel Prescription Digital Therapeutic Option for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease, Alkhouri et al.
Read here.